Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tramadol controlled release - e-Therapeutics

Drug Profile

Tramadol controlled release - e-Therapeutics

Alternative Names: ETS-6103; ETX6103; Tramadol extended release - e-Therapeutics; Tramadol hydrochloride; Tramadol sustained release - e-Therapeutics; Viotra

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator e-Therapeutics
  • Class Anisoles; Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 22 Mar 2016 e-Therapeutics completes a phase IIb trial for Major depressive disorder in the United Kingdom (NCT02014363) prior to March 2016
  • 08 Mar 2016 Biomarkers information updated
  • 07 Jan 2016 Tramadol controlled release - e-Therapeutics is available for licensing as of 07 Jan 2016. http://www.etherapeutics.co.uk/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top